



NETWORK *Notification*

Notice Date: February 24, 2022
To: CareSource PASSE™ Providers
From: CareSource
Subject: COVID-19: Oral Therapies
Effective Date: January, 2022

Beginning on May 12, 2023, this notification is expiring in alignment with the end of the Public Health Emergency.

Summary

In December 2021, the U.S. Food & Drug Administration (FDA) issued emergency use authorizations for Paxlovid (nirmatrelvir and ritonavir) and molnupiravir for the treatment of mild-to-moderate COVID-19. CareSource has worked with our Pharmacy Innovation Partner, Express Scripts, to ensure that Medicaid members have access to these medications through our plans at no cost to our members.

Impact

Prescriptions for Paxlovid and molnupiravir will be covered for CareSource PASSE members within the following limits.

Medication	Quantity Limit	Age Limit
Paxlovid (nirmatrelvir/ritonavir)	30 tablets per claim	Ages ≥12 years
molnupiravir	40 capsules per claim (8 capsules per day)	Ages ≥18 years

Please refer to the FDA Fact Sheet for Healthcare Providers for [Paxlovid](#) or [molnupiravir](#) for additional information about dosing or administration.

Paxlovid and molnupiravir may not be available from every pharmacy. You can search for pharmacies that have these therapies available [here](#).

Importance

By working together to prevent and treat COVID-19, we can mitigate the impact of this disease in our communities. Thank you for your collaboration in providing care to our members.

Questions?

We are here to help you with any questions. For questions, call CareSource PASSE Provider Services at **1-833-230-2100**. We are open Monday through Friday, 8 a.m. to 5 p.m. CST.

Thank you for being a CareSource PASSE provider.

AR-PAS-P-1146987